Composition of Australian Influenza Vaccine for the 2004 season

This report published in Communicable Diseases Intelligence Volume 27, No 4, December 2003 contains the WHO recommendations on the composition of influenza vaccines for 2004 for the Southern Hemisphere season.

Page last updated: 03 December 2003

A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.

In order to select virus strains for the manufacture of Influenza Vaccine for 2004 Season, a meeting of the Australian Influenza Vaccine Committee on Influenza Vaccines was convened on 10   October 2002.

Having considered information on international surveillance by the World Health Organization (WHO), and up-to-date epidemiology and strain characterisation presented at the meeting, the Committee considered that the WHO recommendations on the composition of vaccines for 2004 Southern Hemisphere Season should be followed.


A H1N1 strain: - an A/New Caledonia/20/99(H1N1)-like strain
A/New Caledonia/20/99 (IVR-116) is also recommended as a suitable vaccine strain.
15 µg HA per dose.
A H3N2 strain:

A/Fujian/411/2002(H3N2)-like strain
A/Kumamoto/102/2002 (IVR-135) and A/Wyoming/3/2003 (X-147) are also recommended as suitable vaccine strains.

15 µg HA per dose.
B Strain: B/Hong Kong/330/2001-like strain
B/Brisbane/32/2002 is also recommended as a suitable vaccine strain.
15 µg HA per dose.

Further details available on: www.tga.gov.au/docs/html/aivc2004.htm or
http://www.influenzacentre.org/


This article was published in Communicable Diseases Intelligence Volume 27 No 4, December 2003.

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now

This issue - Vol 27 No4, December 2003